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There is a growing demand for structured reporting inradiology and for the formulation of standard terms to
be used by clinicians and radiologists alike. A study
focusing on computed tomography (CT) reporting of lung
nodules found inconsistency of the reporting of their
margins and presence of calcifications.1 Another study,
comparing imaging terms listed in the Fleischner Society
Glossary2 with their use in medical lexicons including the
International Classification of Diseases, 9th revision, Clinical
Modification (Center of Medicare and Medicaid Services,
Washington, DC), Systematized Nonmenclature of Medicine–
Reference Terminology (SNOMED-RT) (College of Ameri-
can Pathologists, Northfield, IL), and the Unified Medical
Language System (National Library of Medicine, Bethesda,
MD), found low rates of utilization of Fleischner terms
ranging from 3 to 36%.3 On the other hand, when standard-
ized reporting is implemented for imaging a specific disease,
such as seen in the screening for breast cancer, this leads to
improved patient care. It is expected that the creation of a
standardized terminology for the description of an anterior
mediastinal mass suspicious for thymoma and the promotion of
its use will result in improved communication between the
clinician and the radiologist and will ultimately positively im-
pact patient care.
In addition to developing a common language, includ-
ing pertinent information in the radiologic report that will
influence therapy requires knowledge of the disease and is
often disease specific. Because of this, standardized reporting
has been created for specific diseases in a few organs and has
been proven useful. The American College of Radiology
developed the Breast Imaging Reporting and Data System4 to
characterize breast lesions seen on mammography and breast
ultrasound in a standardized manner that correlates with the
underlying histologic findings. The Breast Imaging Reporting
and Data System assigns a percentage probability of malig-
nancy to each category and has gained worldwide acceptance
in its use for guiding clinical management.5 A similar system
has been developed for the ultrasound evaluation of thyroid
nodules, stratifying them into those with imaging findings
more likely to be malignant and those less likely to be
malignant with suggestions for appropriate clinical manage-
ment called Thyroid Imaging and Reporting Data System.6
Although there is preliminary evidence to suggest that
certain imaging findings in thymoma are important for staging or
prognosis, further validation will require the prospective acqui-
sition of data, which will be facilitated by the creation of a
structured radiology report. The following guidelines contain
descriptors that should be included in CT reports of patients with
anterior mediastinal masses in whom thymoma is considered in
the differential diagnosis. Corresponding representative images
are included for clarity and consistency. Pertinent negatives with
regard to these descriptors are just as important. Consistent use
of these descriptors will help establish a common reporting
language that will be used and accepted by clinicians as they
make management decisions regarding their patients with thy-
moma and facilitate further research.
METHODS
The process used in development of this document was
designed to represent a broad consensus within the community
of clinicians and researchers interested in thymic diseases. A
core workgroup (Edith M. Marom, Melissa L. Rosado-de-Chris-
tenson, John F. Bruzzi, Masaki Hara, Joshua R. Sonett, and
Loren Ketai) reviewed the existing literature as well as existing
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standards for chest radiology that applied or could be adapted to
achieving consistency in reporting imaging findings in anterior
mediastinal masses. This group drafted proposed standard report
terms and definitions. These were refined at an International
Thymic Malignancy Interest Group (ITMIG) Definition and
Terminology workshop on November 16, 2010, which was
supported by the International Association for the Study of Lung
Cancer. After distribution to all ITMIG members for comment,
the final document was approved and adopted by ITMIG mem-
bers in February 2011.
Review of Existing Studies
The Masaoka staging system and its variants7,8 have
been shown to strongly correlate with prognosis,8–10 yet
staging is often only established postoperatively. Patients
with locally advanced thymoma may receive neoadjuvant
chemotherapy to enable effective resection,9,11 as complete
resection, even of advanced disease, improves survival.7,12
Currently, it is recommended that patients with stage III and
IV thymoma should receive neoadjuvant therapy.13–18 Histor-
ically, mediastinal imaging has been considered to have
limited value in the staging of patients with thymoma. This
may have been due to the limitations of older imaging
techniques and the rarity of thymoma. These factors likely
influenced scientific publication and limited the number of
published case studies on the imaging of thymoma, which in
turn decreased the statistical power of these studies.
CT is currently considered the preferred imaging mo-
dality for the initial assessment and follow-up of patients with
thymoma.19 In the last decade, CT technique has improved
dramatically resulting in routine rapid acquisition of thin-
section slices enabling high quality image reformations in
multiple planes. This resulted in improved visualization of
these tumors, allowing assessment of internal lesion charac-
teristics as well as detailed visualization of the tumor’s
relationship to surrounding structures.
Promising studies have been published in the last decade,
taking advantage of modern CT imaging techniques. These
studies have shown that some CT characteristics correlate with
aggressive tumor behavior and higher stage. To the best of our
knowledge, only two have correlated the CT appearance of
thymoma with Masaoka staging.20,21,21a One study assessed 50
patients with thymoma21,21a and found that invasive thymomas
were more likely to be larger and have low attenuation regions,
calcifications, and lobulated and irregular contours when com-
pared with low-stage thymomas. A later study assessed 99
patients with thymoma20 and found multiple factors associated
with advanced disease (stages III and IV): large size, lobulated
contours, heterogeneous attenuation, calcifications, infiltration of
surrounding mediastinal fat, tumor abutting 50% of a medi-
astinal structure, adjacent lung abnormalities, and pleural effu-
sion. However, after performing multivariate analysis, larger
tumor size, lobulated contours, and fatty infiltration surrounding
the tumor were the only imaging findings that were likely to
correlate with higher stage disease, i.e., stage III or IV.20
Thymomas are classified histologically by the World
Health Organization (WHO) classification. Although the clin-
ical use of the WHO classification is debatable because of
lack of adequate reproducibility and clinical predictive value
that was found in some studies,10 several CT studies have
correlated CT appearance with the WHO histologic classifi-
cation. Two studies that evaluated 45 and 76 patients with
thymoma22,23 found that lobulated and irregular tumor con-
tours were associated with more aggressive disease, although
this was not confirmed by a third study24 that evaluated 48
patients with thymoma.
The above imaging studies are promising. In fact, some
clinicians already use large tumor size, tumor heterogeneity,
and tumor lobulation to help identify patients who should
receive neoadjuvant therapy before attempted resection.
However, much larger studies correlating the relationship of
imaging findings of thymoma with its biologic behavior are
needed. Such studies will have to be performed on an inter-
national basis as despite thymoma being the most common
primary neoplasm of the anterior mediastinum, it only ac-
counts for less than 1% of all adult malignancies.25
RECOMMENDATIONS
We believe that each CT report of a mediastinal mass
suspicious for thymoma or of newly diagnosed thymoma should
include the following data about the primary mass and its
surrounding structures: lesion location and size in the x, y, and z
axis, description of the lesion contour (smooth or lobulated),
presence or absence of heterogeneous attenuation, calcifications,
infiltration of surrounding mediastinal fat, and tumor abutting
50% of an adjacent mediastinal structure and direct invasion
into a vessel lumen. The following information regarding the
surrounding structures must also be included: diaphragmatic
elevation (consistent with phrenic nerve involvement), adjacent
lung abnormalities, pleural effusion, pleural nodule or nodules,
lymph node enlargement, and findings suggestive of distant
metastatic disease (i.e., lung, liver, adrenal, or peritoneal nod-
ules). If these variables are prospectively and consistently re-
corded, they can be used to create a table or drop down menu to
be used in future structured reports (Tables 1 and 2). In addition,
if all these data are routinely captured in radiologic reports of
cases of thymoma, retrospective studies could be performed
using the information contained in these reports.
Definitions of Thymoma Report Terms
Primary Tumor Size
We recommend documenting the three axes of tumor
size to mirror information that is consistently contained in
pathology reports of excised thymomas. The axial slice cho-
sen for measurement is that which demonstrates the longest
tumor dimension. The short axis is perpendicular to the long
axis on the same slice (Figure 1). Because tumor orientation
does not always conform to strict sagittal or coronal refor-
mats, the superior-inferior dimension of the tumor should be
obtained by subtracting the lowest from the highest bed
position in which the primary tumor is seen (Figure 1).
Location
It is expected that most of these lesions will be located
in the prevascular anterior mediastinum. Some of these le-
sions are unilateral, whereas others cross the midline involv-
ing both sides of the mediastinum.
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Contour
A lesion contour is considered smooth in the absence of
spiculation, ill-defined borders, or lobulation. Smooth lesions
are typically spherical or ovoid in shape, but lesion contours
may also conform to the shape of the adjacent mediastinum.
A lobulated contour is one that exhibits one or more lobula-
tions, characterized as convex tumor contours with adjacent
notches between tumor lobules (Figure 2).
Attenuation
Thymomas may demonstrate homogeneous or hetero-
geneous attenuation. Heterogeneous attenuation often mani-
fests as areas of low attenuation within the tumor and should
be assessed on soft tissue or mediastinal windows. Adminis-
tration of contrast will help demonstrate tumor heterogeneity
and is recommended if not contraindicated (Figure 3). Cystic
thymomas exhibit intrinsic low attenuation manifesting as
homogeneous water attenuation surrounded by the soft tissue
tumor capsule. These lesions may also exhibit internal soft
tissue septa. The presence of mural soft tissue nodules in a
cystic anterior mediastinal mass is one of the characteristic
manifestations of cystic thymoma.
Calcifications
Calcifications of any pattern, including curvilinear,
punctate, or coarse, have been associated with more advanced
disease and should be described and characterized. Viewing
the same image at a different window level, such as with bone
window, may accentuate the differences between intravascu-
lar contrast and tumor calcification (Figure 4).
Infiltration of Surrounding Mediastinal Fat
For a tumor to be characterized as infiltrating the sur-
rounding fat, it needs to only infiltrate the fat in one location and
not necessarily along its entire circumference. Such neoplasms
may exhibit irregular borders. Tumors that abut the mediastinal
TABLE 1. Documentation of Primary Tumor Characteristics
Variable Menu Option
Size (cm) x axis (longest dimension on
axial slice)
y axis (perpendicular to longest
dimension)
z axis (craniocaudal dimension)
Contour Smooth
Lobulated
Internal density Homogenous
Heterogeneous
Cystic
Calcification Yes
No
Infiltration of surrounding fat Yes
No
Abutment of 50% of a mediastinal Yes (list which structure/s)
structure with loss of fat plane No
Additional mediastinal Yes (list)
structures the tumor abuts No
Direct vascular endoluminal Yes (list vessel name)
invasion No
TABLE 2. Documentation of Involvement of Surrounding
Structures
Variable Menu Option
Abnormalities in adjacent lung parenchyma Yes
No
Presence of a pleural effusion Unilateral
Bilateral
No
Presence of a pleural nodule No
Unilateral/bilateral
1
2–5
5/diffuse
Mediastinal lymph node enlargement
(1 cm in short axis on an axial image)
Yes (list location according
to node map26)
No
Abutment at the expected location of the
phrenic nerve
Yes
No
Elevated hemidiaphragm Yes
No
Presence of a pulmonary nodule Yes
No
Extrathoracic suspected metastases Yes (list location)
No
FIGURE 1. Tumor size measurement. The measurement is
obtained on the axial slice that demonstrates the tumor’s
largest diameter; in this case, the largest diameter is 4 cm.
The short axis perpendicular to it is 3.5 cm. Tumor ranged
in superior to inferior orientation from bed position 197 to
149 (197149  48 mm) and thus the superior to inferior
dimension is 4.8 cm. Thus, tumor size should be reported as
4.0  3.5  4.8 cm, with the last measurement represent-
ing the superior to inferior dimension.
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FIGURE 2. Schematic and computed tomography (CT) examples of contour. A, Smooth contour. B, Smooth contour con-
forming to the mediastinal structure the lesion abuts without evidence of lobulation. C, Contrast-enhanced chest CT (soft tis-
sue window) showing a tumor that conforms to the mediastinal structure it abuts. D, Lobulated contour with single sharp
notch. E, Contrast-enhanced chest CT (soft tissue window) showing lobulated tumor due to the lateral sharp notch (white ar-
row) whereas medially the contour is smooth and conforms to the shape of the adjacent mediastinum (black arrowheads). F,
Lobulated contour with multiple lobulations. G, CT image of a multilobulated tumor extending into lung parenchyma (white
arrows point at lobulations).
FIGURE 3. Attenuation. Contrast-enhanced chest com-
puted tomography (CT) (soft tissue window) of a heteroge-
neous thymoma at the level of the pulmonary trunk. Arrows
point to two of the many small low attenuation regions
within the mass.
FIGURE 4. Calcification. Contrast-enhanced chest computed
tomography (CT) (soft tissue window) at levels set between
bone and mediastinal window. Curvilinear high-density regions
(black arrows) are due to calcifications as they do not conform
to the expected morphology of an opacified blood vessel, and
most are of higher attenuation than opacified blood in the left
atrium (LA) and ascending aorta (Ao).
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vessels without an intervening fat plane are not considered as
infiltrating of surrounding fat, as the mediastinal fat that typi-
cally surrounds the vessel cannot be evaluated for infiltration if
it cannot be visualized (Figure 5).
Tumor Abutting >50% of Mediastinal Structure
To maintain consistency in imaging reports, vessel
abutment should be described as the percentage of the vessel
circumference that is touched by the adjacent tumor without
an intervening tissue plane (Figure 6).
Direct Vascular Invasion
Vascular invasion is rarely seen but may manifest as
direct extension of the tumor into a vessel lumen (Figure 7).
FIGURE 5. Infiltration of mediastinal fat. Coronal oblique
reformatted contrast-enhanced chest computed tomography
(CT) (soft tissue window) shows the thymoma (T) with infil-
tration of surrounding mediastinal fat (black arrows). Notice
that the attenuation of the mediastinal fat further away from
the tumor (arrowheads) is lower than that immediately adja-
cent to the lesion.
FIGURE 6. Abutment of vessels. Contrast-enhanced chest
(CT) (soft tissue window) demonstrates the thymoma (T)
nearly completely encasing the right brachiocephalic vein
(white arrow), whereas only abutting about 30% of the aorta
(A) circumference. Arrowhead: contrast filled collateral vein.
FIGURE 7. Vessel invasion. Contrast-enhanced chest com-
puted tomography (CT) (soft tissue window) at the level of
the pulmonary trunk (P) demonstrates a thymoma in the
anterior mediastinum (arrowhead) with direct invasion (seen
on a more superior slice) into the superior vena cava (white
arrow). Note soft tissue attenuation of the intracaval mass
similar to that of the primary tumor.
FIGURE 8. Lymph node enlargement. Contrast-enhanced
chest computed tomography (CT) (soft tissue window) at
the level of the aortic arch (A) demonstrates the thymoma
(T) and adjacent mildly enlarged ipsilateral mediastinal
lymph nodes (white arrows). At surgery, no malignancy was
found within these lymph nodes.
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When present, any appreciable narrowing or deformity of the
vessel lumen should be described as well.
Mediastinal Lymph Node Enlargement
The presence and nodal stations of mediastinal lymph
node enlargement should be noted in the report,26 as removal
of any enlarged lymph nodes at surgery is recommended.27
The definition of mediastinal lymph node enlargement is a
short-axis diameter of a lymph node greater than 1 cm on an
axial image (Figure 8).
Adjacent Lung Abnormalities
Adjacent lung abnormalities such as intrapulmonary
extension of tumor are rarely appreciated on CT and are
usually detected intraoperatively. The most common pulmo-
nary abnormality seen on chest CT is compressive atelectasis
by the adjacent tumor, but this may be difficult to differen-
tiate from direct extension of tumor into lung (Figure 9).
Pleural Effusion
Pleural effusions are not common in patients with
thymoma. However, presence or absence of pleural effusions
should be documented on the report as they are more fre-
quently associated with thymic carcinoma and metastatic
pleural involvement by primary neoplasms other than thy-
moma (Figure 9).
Diaphragmatic Elevation
Inclusion of the phrenic nerve in the resection may com-
promise pulmonary function and may lead to serious postoper-
ative complications.28 Preoperative documentation of phrenic
nerve involvement is of utmost importance as affected patients
may receive preoperative chemotherapy before surgery to allow
complete tumor resection of disease without resection of the
phrenic nerve, thus leading to a favorable functional and survival
benefit. Therefore, elevation of the hemidiaphragm should be
documented in the report. In addition, tumor abutting the ana-
tomic location of the course of the phrenic nerve should also be
mentioned. The phrenic nerve courses over the brachiocephalic
artery, posterior to the subclavian vein, and then crosses anterior
to the hilum, over the pericardium covering the right atrium
(right phrenic nerve) or left ventricle (left phrenic nerve) to the
diaphragm, where it divides into branches which pierce that
muscle and are distributed to its under surface (Figure 10).
Pleural Nodules
Metastatic thymoma typically involves the pleura and
manifests as soft tissue pleural nodules that range from small
lentil-shaped nodules to large pleural masses and can prog-
ress to circumferential nodular pleural thickening with in-
volvement of the interlobar fissures. Solid pleural metastases
(stage IVa) should be distinguished from pulmonary paren-
chymal metastases (stage IVb). Pleural nodules are disposed
along the anatomic location of the pleural surfaces and are
best assessed on the lung window in cases of early disease.
Intraparenchymal pulmonary nodules29 are completely sur-
rounded by lung parenchyma (Figure 11).
FIGURE 9. Pulmonary parenchymal involvement. Contrast-
enhanced chest computed tomography (CT) (soft tissue win-
dow), at the level of the right pulmonary artery (rp), shows
a thymoma (T) compressing the middle lobe bronchus with
resultant atelectasis of the middle lobe. The atelectatic mid-
dle lobe is seen between the tumor edge (black arrowheads)
and the right major fissure (white arrows). It is difficult to
determine whether there is direct tumor invasion into the
lung parenchyma at this site. Note the associated right pleu-
ral effusion (e).
FIGURE 10. Phrenic nerve in-
volvement. A, Posterior anterior
chest radiograph of newly diag-
nosed thymoma demonstrates a
large mediastinal mass (M) with
associated elevation of the left
hemidiaphragm (arrowhead). B,
Contrast-enhanced chest computed
tomography (CT) (soft tissue win-
dow) at the level of the left pulmo-
nary artery (L) demonstrates the
thymoma (M) abutting the entire
left side of the mediastinum ante-
rior to the hilum, this location is in
the expected course of the left
phrenic nerve.
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Distant Metastases
Distant metastases are uncommon at presentation and
constitute stage IVb disease. The most common site is the
lung followed by the liver, lymph nodes, and bone.30
CONCLUSION
This article provides a lexicon of terms that should be
consistently used for describing mediastinal masses suspected
of representing a thymoma. Knowledge of the imaging fea-
tures of high-stage thymomas as well as the correct use of
these terms will add value to the CT report, will facilitate
communication between clinicians and radiologists, and will
allow the radiologist to play an important role in helping the
clinician make management decisions for their patients with
thymoma including the use of preoperative therapy. Docu-
mentation of the above imaging features of thymoma pro-
vides the basis for structured reporting and a database for
collected newly diagnosed thymoma cases that permits fur-
ther research.
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FIGURE 11. Pleural and pulmonary metastasis. Contrast-
enhanced chest computed tomography (CT) (lung window)
demonstrates the thymoma (T) abutting the pulmonary
trunk (*). There is a pleural metastasis within the left major
fissure (PM), a left pleural effusion (e), and a pulmonary
nodule (black arrow) surrounded by lung.
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